About Bigfoot Biomedical
Bigfoot Biomedical provides solutions for individuals with Type 1 and Type 2 diabetes who need insulin therapy through a digital drug delivery platform that simplifies insulin management. This platform operates as a service, offering ongoing support and remote monitoring, allowing healthcare providers to track patients' health data efficiently. Unlike competitors, Bigfoot Biomedical uses a subscription-based model that ensures continuous access to its services, enhancing value for users. The company's goal is to make diabetes care simpler and more accessible, ultimately reducing the burden of diabetes and improving health equity.
Milpitas, CaliforniaHeadquarters
2014Year Founded
$224.7MTotal Funding
DEBTCompany Stage
Data & Analytics, Enterprise Software, HealthcareIndustries
51-200Employees
Risks
Increased competition from Surf Bio's drug stabilization platform in low-income countries.
Challenges in integrating technology with Abbott's systems post-acquisition.
Narrowing focus to pen-based systems may limit market opportunities.
Differentiation
Bigfoot Biomedical offers a comprehensive digital drug delivery platform for insulin management.
The company integrates Abbott's FreeStyle Libre CGM for real-time glycemic alerts.
Bigfoot Biomedical employs a subscription model for continuous support and monitoring.
Upsides
Integration with AI-driven analytics enhances personalized insulin dosing capabilities.
The rise of telehealth expands Bigfoot's remote monitoring capabilities.
FDA's focus on digital health accelerates Bigfoot's product development.
Funding
Total raised$224.70 M
Latest valuation$142.50 M
StageDEBT
DEBT
2/28/2021$28
LATE VC
2/28/2021$28
$142.50 MSERIES C
5/31/2020$10
$50.00 MSERIES A
9/30/2016$36
$177.50 MSEED
10/31/2014$2
$10.00 M